Mr. Michel Habib

Co-Founder, Managing General Partner, ALIVE Israel HealthTech Fund. Michel is a seasoned Venture Capitalist and senior executive investing in BioMed, expert in value building throughout the whole spectrum of startup companies development, with a track record of successful exits of over 1.5 $Bn.
Former advisor to Consensus Business Group Ltd, a multi Billion, London based, family office. Former CEO of Hadasit Bio-Holdings (HDST), member of the BOD of Epitomee (TASE IPO, EPIT), former member of the BOD of Enlivex (Nasdaq, ENLV), Kahr Medical, Minovia, Omnix, Eximore, Meditate (Acquired by Olympus $309M), Xenia Ventures and VLX Incubator, served as Chairman of Cellcure (Nasdaq, LCTX) (Acquired by Roche Genentech $670M) and led investment in Adicet Bio (Nasdaq ACET).Former Managing General Partner at MaC LP VC Funds, with over $100M under management, with significant exits (Lumenis, MST, Endochoice, Peptron).Former Elron’s BD Director, managing the Medical Devices sector (Medingo, Given Imaging). Established and headed the Israel investment banking activity of ING Barings, served as VP Investment Banking at Cukierman & Co.
During the 90’s served as Israel’s Consul for Economic affairs in Boston, and as Commercial Attaché to South Korea. As Officer (Academic Reserve, Captain Res.) in the IDF Navy, managed development of advanced Naval systems for the Navy’s elite unit.
Mr. Habib holds a BsC in Aeronautical Engineering from the Technion. He is a graduate from Israel’s foreign service economic Cadet school, member of the Technion Alumni “100 Club” and graduate from the Global Executive Program on Negotiation (PON) at Harvard Law School.Michel is a member of the 8400 Health Network.